Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
72 studies found for:    Melanoma (women OR woman OR female)
Show Display Options
Download search resultsDownload the search results for:
Melanoma (women OR woman OR female) (72 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Completed Illness Related Distress in Women With Clinically Localized Cutaneous Melanoma
Condition: Melanoma
Intervention: Behavioral: questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided
2 Completed Inflammatory Response and Tissue Fibrosis/ Lymphatico-venous Bypass
Conditions: Breast Cancer;   Genitourinary Cancer;   Malignant Female Reproductive System Neoplasm;   Melanoma;   Sarcoma
Intervention: Procedure: Punch Biopsy
3 Recruiting Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Quality-of-Life Assessment
4 Recruiting Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Bevacizumab;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis
5 Recruiting Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery
Condition: Melanoma (Skin)
Interventions: Drug: dasatinib;   Other: laboratory biomarker analysis
6 Recruiting Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib;   Other: Laboratory Biomarker Analysis
7 Completed Vaccine Therapy in Treating Patients With Metastatic Cancer
Conditions: Lung Cancer;   Adult Soft Tissue Sarcoma;   Colorectal Cancer;   Bone Cancer;   Ovarian Sarcoma;   Melanoma;   Colon Cancer;   Rectal Cancer;   Breast Cancer;   Eye Cancer;   Uterine Sarcoma
Interventions: Drug: interleukin-2;   Drug: MAGE-12 peptide vaccine;   Drug: Montanide ISA-51
8 Completed
Has Results
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
9 Recruiting Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma
Condition: Metastatic Melanoma
Intervention: Radiation: WBRT
10 Completed SWOG-9430: Surgery in Treating Patients With Metastatic Melanoma
Condition: Melanoma (Skin)
Intervention: Procedure: Surgery
11 Recruiting Neurotropic Melanoma of the Head and Neck
Condition: Neurotropic Melanoma of the Head and Neck
Interventions: Other: Observation;   Radiation: Radiation Therapy
12 Terminated Ultraviolet Light Exposure and Immunosuppression in Cutaneous Melanoma
Condition: Melanoma
Intervention:
13 Recruiting A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Condition: Melanoma
Interventions: Biological: Poly-ICLC;   Biological: Peptides
14 Completed Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Melanoma
Condition: Melanoma (Skin)
Interventions: Genetic: comparative genomic hybridization;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Other: immunohistochemistry staining method
15 Recruiting Dendritic Cell Activating Scaffold in Melanoma
Condition: Melanoma
Intervention: Biological: WDVAX
16 Completed Everolimus in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Intervention: Drug: everolimus
17 Suspended Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Melanoma of the Eye
Conditions: Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Ocular Melanoma With Extraocular Extension;   Recurrent Uveal Melanoma;   Small Size Posterior Uveal Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Uveal Melanoma
Interventions: Drug: Cabozantinib S-malate;   Drug: Temozolomide;   Drug: Dacarbazine;   Other: Laboratory Biomarker Analysis
18 Active, not recruiting Dinaciclib in Treating Patients With Stage IV Melanoma
Conditions: Acral Lentiginous Malignant Melanoma;   Lentigo Maligna Malignant Melanoma;   Mucosal Melanoma;   Nodular Malignant Melanoma;   Recurrent Melanoma;   Stage IV Melanoma;   Superficial Spreading Malignant Melanoma
Intervention: Drug: dinaciclib
19 Recruiting Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Biological: Recombinant Interferon Alfa-2b;   Other: Laboratory Biomarker Analysis
20 Suspended High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: recombinant interferon alfa;   Other: clinical observation

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years